Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Technologies, Inc. (NASDAQ: IRTC) generates frequent news as a digital health care company focused on long-term ambulatory cardiac monitoring and data-driven arrhythmia detection. News coverage commonly highlights clinical study results, financial performance, product-related updates for the Zio long-term continuous monitoring (LTCM) service, and the company’s participation in major medical and investor conferences.
Many announcements center on real-world evidence and clinical research. iRhythm regularly reports data from large-scale analyses and trials such as CAMELOT, AVALON, AMALFI, and studies presented at the American Heart Association Scientific Sessions, the Asia Pacific Heart Rhythm Society meetings, and other scientific forums. These updates often explore topics like diagnostic yield compared with other monitoring modalities, performance in diverse patient populations, home-based self-application of Zio devices, and earlier arrhythmia detection in at-risk groups, including those with cardio-kidney-metabolic or chronic kidney disease profiles.
Investors and clinicians following IRTC news will also find quarterly earnings releases, guidance updates, and commentary on operational trends in the company’s core Zio LTCM business, mobile cardiac telemetry initiatives, and international expansion. Additional items include information on investor presentations at healthcare conferences and updates on corporate policies or governance disclosed through press releases linked to SEC filings.
This news page aggregates these developments in one place, allowing readers to review iRhythm’s latest clinical evidence, business updates, and strategic commentary over time. For those tracking digital health, ambulatory ECG monitoring, and AI-enabled cardiac diagnostics, the IRTC news feed provides ongoing insight into how the company presents its technology, research findings, and market priorities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
iRhythm Technologies (NASDAQ:IRTC) announced the release of its financial results for Q1 2023 on May 4, 2023, post-market close. The event will be followed by a live conference call at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the webcast on the company’s investor relations website.
iRhythm is recognized for developing advanced digital health solutions aimed at disease detection, prevention, and prediction. Their technology integrates wearable biosensors and cloud-based analytics with proprietary algorithms to generate clinically actionable insights from cardiac data, enhancing patient care.
iRhythm Technologies, Inc. (NASDAQ:IRTC) has released its 2022 Environmental, Social, and Governance (ESG) Report, highlighting its commitment to sustainable growth. President and CEO Quentin Blackford emphasized the role of ESG initiatives in supporting the company’s mission and values. Key achievements in the report include:
- Advancing Health Equity Task Force: Established to improve access to care and address social determinants of health.
- Diversity, Equity, Inclusion, and Belonging (DEIB): Launched new initiatives leading to 48% of employees identifying as ethnically diverse.
- Climate Reporting: Disclosed 2022 greenhouse gas emissions and plans for further assessments.
The report outlines a strategic focus for ESG initiatives over the next three years, supported by formal board oversight.
iRhythm Technologies (NASDAQ: IRTC), a leader in digital health, presented transformative findings at the ACC.23/WCC conference concerning its Zio XT monitoring system. The CAMELOT study reveals Zio XT offers the highest diagnostic yield and quickest time to diagnosis for arrhythmias, alongside lower retesting and healthcare utilization rates compared to other monitors. The study analyzed Medicare data from 287,789 patients, establishing Zio XT’s superiority over Holter and other monitoring options. Other significant studies highlighted include comparisons of Zio XT to the next-generation Zio monitor, which showed improved patient comfort and performance.